Safety, tolerability and pharmacokinetic profile of single and multiple oral doses of arterolane (RBx11160) maleate in healthy subjects

Journal of Clinical Pharmacology

Volumn 54, Issue 4, 2014, Pages 386-393

  Saha, Nilanjan ^a   Moehrle, Joerg J ^b   Zutshi, Anita ^a   Sharma, Pradeep ^c   Kaur, Pawandeep ^a   Iyer, Sunil S ^c  

^a RANBAXY RESEARCH LABORATORIES   (India)

^b International Center Cointrin   (Switzerland)

^c Clinical Pharmacology and PharmacokineticsHaryana HSIDC   (India)

Author keywords

arterolane maleate; multiple rising dose; OZ277; pharmacokinetics; RBx11160; safety; single rising dose

Indexed keywords

ARTEROLANE; BILIRUBIN; PLACEBO;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; AUDIOMETRY; CAUCASIAN; CONTROLLED STUDY; CROSSOVER PROCEDURE; DERMATITIS; DIARRHEA; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG ACCUMULATION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ERYTHRODERMA; FEMALE; FOOD; FOOD DRUG INTERACTION; GROUPS BY AGE; HEADACHE; HUMAN; LABORATORY TEST; LIPID DIET; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; POSITIONAL DIZZINESS; RANDOMIZED CONTROLLED TRIAL; RASH; SINGLE DRUG DOSE; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

ARTEROLANE MALEATE; MULTIPLE RISING DOSE; OZ277; PHARMACOKINETICS; RBX11160; SAFETY; SINGLE RISING DOSE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTIMALARIALS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; FOOD-DRUG INTERACTIONS; HEALTHY VOLUNTEERS; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; MALE; MIDDLE AGED; PEROXIDES; SPIRO COMPOUNDS; YOUNG ADULT;

EID: 84898660982     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.232     Document Type: Article

References (12)

1. Report of the 2008 Artemisinin Enterprise Conference; October 8-10 York UK accessed at http://www.york.ac.uk/org/cnap/artemisiaproject/pdfs/ AEconference-report-web.pdf
2. WHO facts on ACTs (artemisinin-based combination therapies); January 2006 update accessed at http://www.searo.who.int/LinkFiles/Drug-Policy-RBMInfosheet- 9.pdf
3. Van Noorden R,. Demand for malaria drug soars. Nature. 2010; 466: 672-673.
4. Vennerstrome JL, Arbe-Barnes S, Brun R, et al. Identification of an antimalarial synthetic trioxolane drug development candidate. Nature. 2004; 430: 900-904. (Pubitemid 39119218)
5. Snyder C, Chollet J, Santo-Tomas J, et al. In vitro and in vivo interaction of synthetic peroxide RBx11160 (OZ277) with piperaquine in Plasmodium models. Exp Parasitol. 2007; 115: 296-300. (Pubitemid 44828070)
6. Artemisinin consortium, Medicines for Malaria Venture, Annual Report 2006. URL: http://www.dfid.gov.uk/r4d/PDF/Outputs/MMV/annual-report-2006.pdf (accessed on Nov 26, 2011).
7. Gautam A, Ahmed T, Sharma P, et al. Pharmacokinetics and pharmacodynamics of arterolane maleate following multiple oral doses in adult patients with P. falciparum malaria. J Clin Pharmacol. 2011; 51: 1519-1528.
8. Uhlemann AC, Wittlin S, Matile H, et al. Mechanism of antimalarial action of the synthetic trioxolane RBX11160 (OZ277). Antimicrob Agents Chemother. 2007; 51: 667-672. (Pubitemid 46185288)
9. Colburn WA,. Estimating the accumulation of drugs. J Pharm Sci. 1983; 72: 833-834. (Pubitemid 13076423)
10. Gilbaldi M, Perrier D,. Pharmacokinetics. 2nd edition. New York: Marcel Dekker, 1982. pp 117-119.
11. Bangchang KN, Karbwang J, Thomas CG, et al. Pharmacokinetics of artemether after oral administration to healthy Thai males and patients with acute, uncomplicated falciparum malaria Br J Clin Pharmacol. 1994; 37: 249-253. (Pubitemid 24212184)
12. Valecha N, Looareesuwan S, Martensson A, et al. Arterolane, a new synthetic trioxolane for treatment of uncomplicated Plasmodium falciparum malaria: a phase II, multicenter, randomized, dose-finding clinical trial. Clin Infect Dis. 2010; 51: 684-691.